We provide a method to simultaneously screen a library of antibody fragments for binding affinity and cytoplasmic solubility by using the Escherichia coli twin-arginine translocation pathway, which has an inherent quality control mechanism for intracellular protein folding, to display the antibody fragments on the inner membrane.
Antibodies engineered for intracellular function must not only have affinity for their target antigen, but must also be soluble and correctly folded in the cytoplasm. Commonly used methods for the display and screening of recombinant antibody libraries do not incorporate intracellular protein folding quality control, and, thus, the antigen-binding capability and cytoplasmic folding and solubility of antibodies engineered using these methods often must be engineered separately. Here, we describe a protocol to screen a recombinant library of single-chain variable fragment (scFv) antibodies for antigen-binding and proper cytoplasmic folding simultaneously. The method harnesses the intrinsic intracellular folding quality control mechanism of the Escherichia coli twin-arginine translocation (Tat) pathway to display an scFv library on the E. coli inner membrane. The Tat pathway ensures that only soluble, well-folded proteins are transported out of the cytoplasm and displayed on the inner membrane, thereby eliminating poorly folded scFvs prior to interrogation for antigen-binding. Following removal of the outer membrane, the scFvs displayed on the inner membrane are panned against a target antigen immobilized on magnetic beads to isolate scFvs that bind to the target antigen. An enzyme-linked immunosorbent assay (ELISA)-based secondary screen is used to identify the most promising scFvs for additional characterization. Antigen-binding and cytoplasmic solubility can be improved with subsequent rounds of mutagenesis and screening to engineer antibodies with high affinity and high cytoplasmic solubility for intracellular applications.
Antibodies capable of folding and functioning in the intracellular environment are promising tools for both research and therapeutic applications. They have the ability to modulate protein activity by binding to a target protein inside cells to prevent protein-protein interactions, disrupt protein-nucleic acid interactions, or prevent substrate access to enzymes1-5.
Although antibodies have much potential for intracellular applications, engineering them for proper folding and solubility in the intracellular environment while maintaining the ability to bind to a target antigen is challenging. The reducing cytoplasmic environment prevents the formation of the disulfide bonds normally required for the stable folding of full-length antibodies and antibody fragments, including single-chain variable fragment (scFv) antibodies6,7. A number of directed evolution approaches have been employed to engineer antibodies with high affinities for target antigens8-10. These approaches commonly use phage display, yeast surface display, or bacterial surface display to screen large libraries of antibodies11-13. These methods are powerful and effective for identifying antibodies that bind to targets, yet they depend on the secretory pathway to transport proteins that will be displayed14-16. The secretory pathway translocates unfolded proteins from the reducing cytoplasm into the endoplasmic reticulum lumen in yeast or into the periplasm in bacteria. The proteins then fold under oxidizing conditions and are displayed on the cell surface or packaged into phage particles to screen for binding affinity17,18. As a result, antibodies isolated using these techniques will not necessarily fold well in the cytoplasm, and intracellular solubility must often be engineered separately if the antibodies will be used in intracellular applications.
To improve the efficiency of engineering antibodies that are well folded in the cytoplasm, we previously reported the success of MAD-TRAP (membrane-anchored display for Tat-based recognition of associating proteins), a method for screening an scFv antibody library using Escherichia coli inner-membrane display19. Bacterial inner-membrane display relies on the twin-arginine translocation (Tat) pathway for transporting displayed antibodies, in contrast to other common display methods that use the secretory pathway. The Tat pathway contains a quality control mechanism that only allows soluble, correctly folded proteins to be transported from the E. coli cytoplasm, across the inner membrane, and into the periplasm20,21. Overexpressed Tat substrates (i.e., proteins targeted to the Tat pathway with an N-terminal fusion to the Tat signal peptide ssTorA) that are well folded in the cytoplasm form a long-lived translocation intermediate with the N-terminus in the cytoplasm and the C-terminus in the periplasm19. This allows display of correctly folded Tat substrates, including antibody fragments, on the periplasmic face of the E. coli inner membrane. After removing the outer membrane by enzymatic digestion to generate spheroplasts, antibodies are exposed to the extracellular space (Figure 1). This allows Tat substrates displayed on the inner membrane to be screened for binding to a specific target. Importantly, harnessing the Tat pathway for cell-surface display ensures that only the antibodies in the library that are well folded in the cytoplasm will be interrogated for binding, allowing simultaneous engineering of binding affinity and intracellular folding. In this protocol, we describe how to display an scFv library on the E. coli inner membrane, pan the library against a target antigen, and perform a secondary screen to identify the most promising constituents of the library. While we focus the protocol on scFvs, the method could be applied to engineering any protein whose application requires binding and intracellular folding.
Figure 1. Tat inner-membrane display. In E. coli, scFv antibodies that are expressed as a fusion to the ssTorA signal sequence and correctly folded in the cytoplasm are transported across the inner membrane. A translocation intermediate forms, where the scFvs are anchored in the inner membrane with the N-terminus in the cytoplasm and the C-terminus in the periplasm. The E. coli outer membrane is enzymatically digested to form spheroplasts, thereby exposing the anchored antibodies to the extracellular space and making them available for detection by using an antibody that binds to the C-terminally fused epitope tag on the displayed antibody. Please click here to view a larger version of this figure.
Engineering antibodies for cytoplasmic activity is a difficult task due to the reducing milieu of the cytoplasm, which impedes the formation of stabilizing disulfide bonds6,7. This causes most antibodies to be cytoplasmically inactive unless they are engineered for stability and solubility in the cytoplasm, in addition to being engineered for binding affinity. The existing methods of phage display, bacterial surface display, and yeast surface display methods all use the secretory pathway14-16 for the display of engineered antibodies, but these methods have no means to engineer intracellular folding. Antibodies engineered using inner-membrane display have improved cytoplasmic stability and solubility because the folding quality control of the Tat pathway prevents translocation of antibodies that are poorly folded and unstable in the cytoplasm. This method simplifies the iterative process of engineering intracellular antibodies for affinity and solubility, as the two properties are engineered in one step. Although this method was designed for engineering antibodies with solubility in the reducing intracellular environment, it could also be applied to engineering antibodies to function in non-reducing conditions, since the proteins engineered using this method maintain their folding in the oxidizing environment of the periplasm.
Although this technique simplifies the process of engineering antibodies with high affinity and high cytoplasmic solubility, several limitations are important to consider when using this protocol. When analyzing the secondary screen ELISA signals to identify promising scFv variants, the threshold for discerning between potentially interesting variants and those that may not exhibit adequate antigen-binding is not likely to be apparent until after several clones have been further characterized. It is important to look for improved binding over the parent antibody; however, an abnormally high signal could be indicative of avidity29 or aggregation effects30, a challenge which is not unique to the inner-membrane display screening approach. A key limitation to remember when using this protocol is the inability to recover spheroplasts after panning, as they are non-viable (unpublished data). This necessitates the DNA amplification and transformation steps to recover the antibody-encoding plasmids.
Several critical steps of the protocol enable the simultaneous engineering of folding and binding of antibodies. For screening to be successful, the scFv library being screened must be expressed as a fusion to the ssTorA signal peptide. Without this sequence, antibodies will not be directed to the Tat pathway and thus will not be translocated to the periplasm19. Additionally, it is imperative that a C-terminal epitope tag is fused to the antibodies to allow detection of the displayed antibodies in the binding assays. Clearly, the E. coli strain used to express the scFvs must also have the necessary Tat pathway machinery, but this is true of the commonly used E. coli strains.
Modifications to this protocol are possible to improve its potential to isolate antibodies with the desired characteristics. A subtractive panning step may be completed prior to panning against the target antigen to deplete the scFv library of non-desired constituents. The library spheroplasts can be incubated with magnetic beads coated with BCCP alone or coated with a non-desired protein, and the spheroplasts that bind to those beads can be discarded before screening the remaining unbound spheroplasts for binding to the desired target. As mentioned in the Representative Results, a method to improve the affinity of an isolated scFv is to include a soluble competitor in the panning reaction to compete with the scFvs displayed on the spheroplasts. Because the soluble competitor is a purified protein, no DNA is amplified from it, so only sequences of the scFvs displayed on the spheroplasts will be recovered in the PCR reaction. Additionally, this method could be extended to engineering other types of antibodies or to non-antibody binding proteins.
E. coli inner-membrane display is a powerful platform for engineering antibodies with high affinity and high levels of intracellular solubility. This method is particularly suited for efficient engineering of antibodies designed to function in the intracellular environment. These intracellular antibodies are already being explored as potential therapeutics in a number of fields, including neurodegenerative diseases, cancer, and viral infections31. This technique will enable more widespread use of intracellular antibodies as tools for research and medicine in these fields and any other field where studying a protein target in situ is desired.
The authors have nothing to disclose.
We thank Tomer Zohar for work on scFv screening and characterization assays. A portion of this work was supported by award number F32CA150622 from the National Cancer Institute (to AJK). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.
scFv library | Varies | N/A | A suitable scFv library should be obtained from a commercial or academic source. |
MC4100 E. coli cells | Coli Genetic Stock Center | 6152 | Cells need to be chemically competent or electrocompetent, depending on the selected transformation method. |
Glycerol | Fisher Scientific | BP229-4 | |
Difco dehydrated culture media LB Broth, Miller (Luria-Bertani) | BD | 244610 | |
Chloramphenicol (Cm) | Fisher Scientific | BP904-100 | |
Sodium chloride (NaCl) | Fisher Scientific | BP358-1 | |
Potassium chloride (KCl) | Fisher Scientific | BP366-500 | |
Sodium phosphate, dibasic (Na2HPO4) | Fisher Scientific | BP332-500 | |
Potassium phosphate, monobasic (KH2PO4) | Fisher Scientific | BP362-500 | |
Bovine serum albumin (BSA) | Fisher Scientific | BP9706-100 | |
Sucrose | Fisher Scientific | BP220-1 | |
Tris base | Fisher Scientific | BP1521 | |
Ethylenediaminetetraacetic acid (EDTA), 0.5 M | Fisher Scientific | BP2482-500 | |
Magnesium chloride (MgCl2) | Fisher Scientific | BP214-500 | |
Lysozyme | Sigma Aldrich | L3790-10X1ML | |
Vortex mixer | VWR | 97043-564 | |
Bicine | Fisher Scientific | BP2646100 | |
D-Biotin | Fisher Scientific | BP232-1 | |
Isopropyl β-D-1-thiogalactopyranoside | Fisher Scientific | BP1755-1 | |
BugBuster Master Mix (cell lysis detergent) | EMD Millipore | 71456 | |
Vivaspin 2 MWCO, 3000 daltons | GE Healthcare Sciences | 28932240 | |
Target antigen | Varies | N/A | Purified target antigen may be purchased or produced/purified. |
Dynabeads MyOne Streptavidin T1 | Invitrogen | 65601 | |
Dynamag-2 magnet | Invitrogen | 12321D | |
Tube rotator | VWR | 13916-822 | |
PCR primers | IDT | N/A | Primer sequences are as described in the protocol. |
10X T4 DNA ligase reaction buffer | New England BioLabs | B0202S | |
T4 Polynucelotide kinase (PNK) | New England BioLabs | M0201S | Make sure the T4 ligase buffer used in the primer phosphorylation reaction contains 1 mM ATP. |
5X Phusion HF buffer pack | New England BioLabs | B0518S | |
Deoxynucleotide (dNTP) solution mix, 10 mM each dNTP | New England BioLabs | N0447L | |
Phusion DNA polymerase | New England BioLabs | M0530S | Other high-fidelity polymerases may be used as an alternative, but the annealing temperature in Table 3 must be adjusted. |
C1000 Touch thermal cycler with dual 48/48 fast reaction module | Bio-Rad | 185-1148 | |
Agarose | Promega | V3121 | |
SYBR Safe DNA gel stain | Invitrogen | S33102 | |
Wizard SV gel and PCR clean-up system | Promega | A9281 | |
T4 DNA ligase | New England BioLabs | M0202S | |
Microdialysis membrane filter | EMD Millipore | VSWP04700 | |
Agar | BD | 214030 | |
96-well polystyrene round-bottom cell culture plates | VWR | 10062-902 | |
Costar general polystyrene assay plate lids | Corning | 3931 | |
Microtitre plate shaker | VWR | 12620-926 | |
Costar 96 well EIA/RIA Easy Wash clear flat bottom polystyrene high bind microplate | Corning | 3369 | |
Bel-blotter polycarbonate 96-well replicating tool | Bel-Art Products | 378760002 | |
Instant nonfat dry milk | Quality Biological | A614-1000 | |
Tween 20 (polysorbate 20) | Fisher Scientific | BP337-500 | |
PopCulture reagent (concentrated cell lysis detergent) | EMD Millipore | 71092-3 | |
Monoclonal ANTI-FLAG M2-Peroxidase(HRP) antibody produced in mouse | Sigma Aldrich | A8592 | |
SigmaFast OPD | Sigma Aldrich | P9187-50SET | |
Sulfuric acid (H2SO4), 10N solution | Fisher Scientific | SA200-1 | |
Reynolds Wrap aluminum foil | VWR | 89079-075 | |
BioTek Epoch microplate spectrophotometer | Fisher Scientific | 11120570 |